Singapore, Oct. 24 -- AI Proteins, Inc., a US-based biotechnology company that utilises computational de novo protein design to create therapeutic miniproteins, has entered into a Research Collaboration and License Agreement with Astellas Innovation Management LLC, an affiliate of Japan-based Astellas Pharma Inc., to discover and develop novel miniprotein-based therapeutics.

Under the terms of the agreement, AI Proteins is eligible to receive over $400 million in upfront and milestone payments, plus royalties on net sales of any resulting products.

Under the collaboration, AI Proteins will apply its proprietary AI-driven discovery platform to design and optimise de novo miniproteins against multiple targets. These computationally design...